Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)-CE19-004, Etiologic and Effectiveness Research To Address Polysubstance Impaired Driving; Amended Notice of Meeting, 12256 [2019-06146]

Download as PDF 12256 Federal Register / Vol. 84, No. 62 / Monday, April 1, 2019 / Notices automated collection techniques or other forms of information technology. Comments submitted in response to this notice will be summarized and included in the Agency’s subsequent request for OMB approval of the proposed information collection. All comments will become a matter of public record. Gopal Khanna, Director. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services [CMS–1725–N] Medicare Program; Meeting Announcement for the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests Centers for Medicare & Medicaid Services (CMS), HHS. ACTION: Notice. AGENCY: [FR Doc. 2019–06192 Filed 3–29–19; 8:45 am] BILLING CODE 4160–90–P This notice announces the next public meeting dates for the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (the Panel) on Monday, July 22, 2019 and Tuesday, July 23, 2019. The purpose of the Panel is to advise the Secretary of the Department of Health and Human Services and the Administrator of the Centers for Medicare & Medicaid Services on issues related to clinical diagnostic laboratory tests. DATES: Meeting Dates: The meeting of the Panel is scheduled for Monday, July 22, 2019 from 8:00 a.m. to 4:30 p.m., Eastern Daylight Time (E.D.T.) and Tuesday, July 23, 2019, from 8:00 a.m. to 4:30 p.m., E.D.T. The Panel is also expected to participate in the Clinical Laboratory Fee Schedule (CLFS) Annual Public Meeting for Calendar Year (CY) 2020 on June 24, 2019 in order to gather information and ask questions to presenters. Notice of the CLFS Annual Public Meeting for CY 2020 is published elsewhere in this issue of the Federal Register. Deadline for Registration: The public may attend the Panel meeting in person, view via webcast or listen via teleconference. Beginning Monday, April 8, 2019 and ending Monday, July 1, 2019 at 5:00 p.m. E.D.T., registration to attend the Panel meeting in person may be completed online at https:// cms.gov/Regulations-and-Guidance/ Guidance/FACA/AdvisoryPanelon ClinicalDiagnosticLaboratoryTests.html. On this web page, under ‘‘Panel Meetings,’’ click the ‘‘Register for July 22 through 23, 2019 Panel Meeting’’ link and enter the required information. We refer readers to Section IV. of this notice for additional details related to meeting registration. Webinar, Webcast, and Teleconference Information: Teleconference dial-in instructions, and related webcast and webinar details will be posted on the meeting agenda, which will be available on the CMS website approximately 2 weeks prior to the meeting at https://www.cms.gov/ SUMMARY: DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—CE19–004, Etiologic and Effectiveness Research To Address Polysubstance Impaired Driving; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)–CE19– 004, Etiologic and Effectiveness Research to Address Polysubstance Impaired Driving; May 7–8, 2019; 8:30 a.m.–5:30 p.m., (EDT) which was published in the Federal Register on February 15, 2019, Volume 84, Number 32, page/s/4446–4447. The meeting is being amended to change the meeting location to The W Buckhead, 3377 Peachtree Road, NE, Atlanta, GA 30326]. The meeting is closed to the public. FOR FURTHER INFORMATION CONTACT: Mikel L. Walters, M.A., Ph.D., Scientific Review Official, NCIPC, CDC, 4770 Buford Highway NE, Mailstop F–63, Atlanta, Georgia 30341,(404) 639–0913; mwalters@cdc.gov. The Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Sherri Berger, Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2019–06146 Filed 3–29–19; 8:45 am] BILLING CODE 4163–18–P VerDate Sep<11>2014 17:22 Mar 29, 2019 Jkt 247001 PO 00000 Frm 00067 Fmt 4703 Sfmt 4703 Regulations-and-Guidance/Guidance/ FACA/AdvisoryPanelonClinical DiagnosticLaboratoryTests.html. A preliminary agenda is described in Section II. of this notice. ADDRESSES: The Panel meeting will be held in the auditorium of the Centers for Medicare & Medicaid Services (CMS), Central Building, 7500 Security Boulevard, Baltimore, Maryland 21244– 1850. FOR FURTHER INFORMATION CONTACT: Rasheeda Arthur, Ph.D., (410) 786–3434, email CDLTPanel@cms.hhs.gov. Press inquiries are handled through the CMS Press Office at (202) 690–6145. For additional information on the Panel, refer to the CMS website at https:// www.cms.gov/Regulations-andGuidance/Guidance/FACA/Advisory PanelonClinicalDiagnosticLaboratory Tests.html. SUPPLEMENTARY INFORMATION: I. Background The Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests (the Panel) is authorized by section 1834A(f)(1) of the Social Security Act (the Act) (42 U.S.C. 1395m–1), as established by section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA) (Pub. L. 113–93), enacted on April 1, 2014. The Panel is subject to the Federal Advisory Committee Act (FACA), as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory panels. Section 1834A(f)(1) of the Act directs the Secretary of the Department of Health and Human Services (the Secretary) to consult with an expert outside advisory panel established by the Secretary, composed of an appropriate selection of individuals with expertise in issues related to clinical diagnostic laboratory tests, which may include the development, validation, performance, and application of such tests. Such individuals may include molecular pathologists, researchers, and individuals with expertise in laboratory science or health economics. The Panel will provide input and recommendations to the Secretary and the Administrator of the Centers for Medicare & Medicaid Services (CMS) on the following: • The establishment of payment rates under section 1834A of the Act for new clinical diagnostic laboratory tests, including whether to use ‘‘crosswalking’’ or ‘‘gapfilling’’ processes to determine payment for a specific new test. E:\FR\FM\01APN1.SGM 01APN1

Agencies

[Federal Register Volume 84, Number 62 (Monday, April 1, 2019)]
[Notices]
[Page 12256]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-06146]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Disease, Disability, and Injury Prevention and Control Special 
Emphasis Panel (SEP)--CE19-004, Etiologic and Effectiveness Research To 
Address Polysubstance Impaired Driving; Amended Notice of Meeting

    Notice is hereby given of a change in the meeting of the Disease, 
Disability, and Injury Prevention and Control Special Emphasis Panel 
(SEP)-CE19-004, Etiologic and Effectiveness Research to Address 
Polysubstance Impaired Driving; May 7-8, 2019; 8:30 a.m.-5:30 p.m., 
(EDT) which was published in the Federal Register on February 15, 2019, 
Volume 84, Number 32, page/s/4446-4447.
    The meeting is being amended to change the meeting location to The 
W Buckhead, 3377 Peachtree Road, NE, Atlanta, GA 30326]. The meeting is 
closed to the public.

FOR FURTHER INFORMATION CONTACT: Mikel L. Walters, M.A., Ph.D., 
Scientific Review Official, NCIPC, CDC, 4770 Buford Highway NE, 
Mailstop F-63, Atlanta, Georgia 30341,(404) 639-0913; [email protected].
    The Chief Operating Officer, Centers for Disease Control and 
Prevention, has been delegated the authority to sign Federal Register 
notices pertaining to announcements of meetings and other committee 
management activities, for both the Centers for Disease Control and 
Prevention and the Agency for Toxic Substances and Disease Registry.

Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2019-06146 Filed 3-29-19; 8:45 am]
 BILLING CODE 4163-18-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.